{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Restrict the search for
vitamin a palmitate
to a specific field?
Class (Stereo):
CHEMICAL (RACEMIC)
Acridorex (BS 7573a) is an anorectic agent.
Class (Stereo):
CHEMICAL (ACHIRAL)
Targets:
Ocfentanil, a compound structurally similar to the opioid analgesic fentanyl, was developed in the early 1990’s with the hope that it would provide a better clinical safety profile than fentanyl. The receptor pharmacology of ocfentanil appears to share pharmacodynamic effects with fentanyl and other μ opioid agonists, including analgesia, sedation, and respiratory depression. In rodents, ocfentanil was approximately 2.5 times more potent as an analgesic than fentanyl and had a shorter duration of action. Because the preclinical research suggested that ocfentanil had a better safety profile than fentanyl, it was selected for clinical evaluation. Like other μ opioid agonists, ocfentanil has been reported to produce itching, nausea, sedation, and severe respiratory depression. Chest pain, psychosis, and agitation have also been reported. In humans, however, ocfentanil had a similar potency (3 ug/kg ocfentanil produced effects that were comparable to 5 ug/kg fentanyl) and side-effects profile as fentanyl so further clinical development was discontinued. Ocfentanil is not approved in any country for medical useand is under national control in Canada, the United Kingdom, and China.
Class (Stereo):
CHEMICAL (ACHIRAL)
Recainam is an investigational Class I anti-arrhythmic agent that has been studied for its potential in treatment of heart rhythm disorders. No severe adverse events of intravenous recainam adminstration were reported in a study in patients with frequent ventricular premature complexes (extra heart beats) and nonsustained ventricular tachycardia (abnormally fast heartbeat).
Status:
Investigational
Source:
NCT02342249: Phase 2 Interventional Completed Influenza A
(2014)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Targets:
JNJ-872 is an inhibitor of influenza virus replication that offers a potential for the treatment of pandemic and seasonal influenza.
Class (Stereo):
CHEMICAL (MIXED)
Odalprofen was used as an analgesic. Information about the current use of this compound is not available.
Status:
Investigational
Source:
JAN:LASCUFLOXACIN HYDROCHLORIDE [JAN]
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
LASCUFLOXACIN, a fluoroquinolone derivative, is an antibacterial agent with a broad spectrum of activity against various clinical isolates. It is under development for the treatment of respiratory tract infections and community-acquired pneumonia.
Status:
Investigational
Source:
NCT02764385: Not Applicable Interventional Completed Smoking
(2016)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Status:
Investigational
Source:
INN:mariptiline [INN]
Source URL:
Class (Stereo):
CHEMICAL (RACEMIC)
Mariptiline is an antidepressant compound.
Status:
Investigational
Source:
INN:clonitazene [INN]
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Targets:
Clonitazene is a synthetic opioid analgesic, structurally related to etonitazene. In the USA clonitazene is a schedule I narcotic controlled substance.
Status:
Investigational
Source:
NCT00623363: Phase 2 Interventional Completed Parkinson's Disease
(2007)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Piclozotan (SUN N4057) is a 1,4-benzoxazepine derivative that exhibits sub-nanomolar affinity at serotonin 1A receptor with good selectivity over dopamine D2 and α1-adrenoceptors. Piclozotan reduced levodopa-induced forelimb hyperkinesia by 55% and 69%, respectively, at 1h relative to the control. Piclozotan significantly lengthened the duration of rotational behavior by 26% versus the control and attenuated the increase in striatal levodopa-derived extracellular dopamine levels. Piclozotan, a serotonin 1A agonist, can improve motor complications in patients with advanced Parkinson's disease. Piclozotan has been shown to be neuroprotective against ischemic neuronal damage in animal models. Piclozotan had been in phase II for the treatment of stroke. However, this research has been discontinued.
